Impact of bortezomib-based versus lenalidomide maintenance therapy on outcomes of patients with high-risk multiple myeloma.
Study #: MM20-03
Study Status: Published
Bumma N, Dhakal B, Fraser R, Estrada-Merly N, Anderson K, Freytes CO, Hildebrandt GC, Holmberg L, Krem MM, Lee C, Lekakis L, Lazarus HM, Mian H, Murthy HS, Nathan S, Nishihori T, Parrondo R, Patel SS, Solh M, Strouse C, Vesole DH, Kumar S, Qazilbash MH, Shah N, D'Souza A, Sidana S.
Cancer. 2023, Jul 15: 129(14): 129(14):2179-2191. doi: 10.1002/cncr.34778. Epub 2023, Apr 06. PMCID:PMC10516285.
PMID: 37021929
Abstract